Influence of cancer-related inflammation on plasma disposition of osimertinib in patients with non-small cell lung cancer using the Glasgow prognostic score.

Key Points

• The aim is to explore how cancer-related inflammation affects osimertinib plasma levels in lung cancer patients.
• Evaluated plasma osimertinib concentrations in 36 non-small cell lung cancer patients.
• Investigated both genetic and non-genetic factors influencing these concentrations.
• Assessed CYP3A activity using 4β-hydroxycholesterol as a biomarker.
• Identified a correlation between cancer-related inflammation and altered plasma concentrations of osimertinib.
• Showed variations in CYP3A activity directly influenced osimertinib levels in patients.